Bath Savings Trust Co Purchases 835 Shares of Zoetis Inc. (ZTS)
Bath Savings Trust Co lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 18.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,308 shares of the company’s stock after acquiring an additional 835 shares during the quarter. Bath Savings Trust Co’s holdings in Zoetis were worth $338,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. increased its holdings in Zoetis by 16.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares during the last quarter. Harfst & Associates Inc. increased its holdings in Zoetis by 16.1% in the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after purchasing an additional 260 shares during the last quarter. Guardian Life Insurance Co. of America increased its holdings in Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after purchasing an additional 13 shares during the last quarter. Almanack Investment Partners LLC. bought a new stake in Zoetis in the second quarter valued at about $119,000. Finally, Point72 Asia Hong Kong Ltd bought a new stake in Zoetis in the first quarter valued at about $111,000. Institutional investors own 93.19% of the company’s stock.
ZTS has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $75.00 price objective on Zoetis and gave the company a “buy” rating in a report on Monday, August 14th. Stifel Nicolaus reiterated a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a report on Friday, September 1st. Deutsche Bank AG reiterated a “buy” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. BidaskClub downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 20th. Finally, Cowen and Company set a $60.00 price objective on Zoetis and gave the company a “buy” rating in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $65.76.
Zoetis Inc. (NYSE ZTS) traded up 0.434% on Tuesday, reaching $65.995. The company’s stock had a trading volume of 680,201 shares. The stock has a market cap of $32.28 billion, a price-to-earnings ratio of 37.306 and a beta of 1.02. The firm’s 50-day moving average price is $63.94 and its 200-day moving average price is $60.97. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $66.11.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting analysts’ consensus estimates of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same period in the previous year, the company posted $0.49 EPS. The firm’s revenue was up 5.0% compared to the same quarter last year. On average, equities analysts expect that Zoetis Inc. will post $2.34 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be given a $0.105 dividend. This represents a $0.42 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend is Wednesday, November 8th. Zoetis’s payout ratio is 23.73%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.